Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on ...

Novo Nordisk's GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications.Seana Smith and Brad Smith ...

LISBON, Jan 15 (Reuters) - U.S. private equity fund Lone Star and Portuguese authorities are set to share 1.3 billion euros ($1.34 billion) when Novo Banco makes its first dividend payout in the ...

Columbus joined a slough of cities, states and counties in suing drug companies and pharmacy benefit managers who they say artificially raised insulin prices for decades and profited from it, city ...

Life was getting better for Carlos Campos, 72, a retired machinist who lives with his wife and daughter in Tukwila, Wash. Diagnosed about 20 years ago with type 2 diabetes, he was delighted to see ...

Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, hopes to double the size of its recently acquired contract drugmaker Catalent over five ...

To hear Novo tell it, the outsourcing group OFA shouldn’t be allowed to place liraglutide on its compounding list given that FDA-approved generics to Victoza are available. Further, the OFA has ...

Righting the ship on supply Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive signals” are emerging when it comes to the ...

Tech entrepreneur and Tesla (TSLA, Financials) CEO Elon Musk's disclosure of using weight-loss pharmaceuticalsincluding Eli Lilly's (LLY, Financials) Mounjaro and Novo Nordisk's Ozempichas drawn ...

A diabetic woman has claimed she almost died from an eating disorder after doctors mistook her insulin misuse for 'laziness'. April Longe, 19, from Colchester, developed diabulimia - an eating ...

Novo Nordisk recently announced results for a new weight loss candidate, CagriSema. Data from the trial underwhelmed investors, and Novo stock is down almost 20% on the news. However, investors ...